Study of malondialdehyde as an oxidative stress marker in schizophrenia
DOI:
https://doi.org/10.18203/2320-6012.ijrms20163759Keywords:
MDA, Oxidative stress, SchizophreniaAbstract
Background: Schizophrenia is characterized by distortions in thinking, perception, emotions, language, sense of self and behaviour. It has been demonstrated that free radical-mediated damage has an important role in the pathophysiology of schizophrenia. The present study was undertaken to study malondialdehyde as an oxidative stress marker in first episode and chronic schizophrenic patients.
Methods: 50 patients of first episode schizophrenia and 50 patients of chronic schizophrenia were included in the study. 50 numbers of age and sex matched healthy and apparently normal controls were also selected for study. Blood samples were drawn and analysed for malondialdehyde (MDA) from all participants.
Results: The study shows significant increase in plasma malondialdehyde (MDA) levels in both first episode schizophrenics and chronic schizophrenic patients as compared to controls. When we compared levels of these parameters in first episode schizophrenics and chronic schizophrenics, we did not find significant difference.
Conclusions: Findings in our study is suggesting that increase in the levels of plasma malondialdehyde (MDA) occurs due to increased lipid peroxidation in schizophrenics.
References
Schizophrenia. In: Kaplan and Sadock’s Synopsis of Psychiatry. Tenth Edition. Benjamin James Sadock, Virginia Alcott Sadock. Wolters Kluwer Health. 2010:669-99.
Thara R, Padmavati R, Shrinivasan TN. Schizophrenia. British J Psy. 2004;184:366-73.
Mahadik SP, Evans DR.Is schizophrenia a metabolic brain disorder? Membrane phospholipids dysregulation and its therapeutic implications. Psychiatr Clin N Am. 2003;26:85-102.
Davies SW, Ranjadayalan K. Lipid peroxidation associated with successful thrombolysis. Lancet. 1990;335:741-3.
Domanski L, Pietrzak-Nowacka. Malondialdehyde, uric acid and white cell count as markers of oxidative stress in acute myocardial infarction and coronary insufficiency. Pol. Merkuriusz Lek. 2001;11 (62):121-4.
American psychiatric association DSM-IV.DSM-IV diagnostic criteria for schizophrenia. Diagnostic and statistical manual of mental disorders. 4th ed. Washington. 1994:273-315.
Motghare KS, Bhutey A, Murrhar BB, Gupta M. Lipid peroxidation and glutathione peroxidase in ischemic heart disease. Indian Journal of Clinical Biochemistry 2001;16(2):213-15.
Steinberg D, Parathasarthys. Total antioxidant status and lipid peroxidation in diabetic patients N. Engl. J. Med. 1989;320:915-24.
Victor IR. Mental disorders, In: Harrison’s principles of Internal Medicine. 16th edition.Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. New Delhi: McGraw – Hill. 2005;2547-61.
Ustundag B, Atmaca M, Kirtas O. Total antioxidant response in patients with schizophrenia. Psych Clin Neurosci. 2006;60(4):458-64.
Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Denise Evans, David F. Horrobin et al. Essential polyunsaturated fatty acid and Lipid peroxide Levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry. 2003;53:56-64.
Khan M. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia Research. 2003; 58(1):1.
Mahadik SP, Mukherjee S, Scheffer R, Elizabeth E. Correnti and Mahadik JS. Elevated Plasma Lipid Peroxides at the Onset of Nonaffective Psychosis. Biological Psychiatry. 1998;43(9):674-79.
Surapaneni KM. Status of Lipid Peroxidation, Glutathione, Ascorbic Acid,Vitamin E and Antioxidant Enzymes in Schizophrenic Patients. J Clinical and Diagnostic Research. 2007;1(2):39-44.
Uma Devi P, Chinnaswamy P. Oxidative injury and enzymic antioxidant misbalance in schizophrenics with positive, negative and cognitive symptoms. African Journal of Biochemistry Research. 2008;2(4):92-7.
LI Hui-chun, CHEN Qiao-zhen, MA Ying, ZHOU Jun-fu. Imbalanced free radicals and antioxidant defense systems in schizophrenia: A comparative study. Journal of Zhejiang University SCIENCE B 2006;7(12):981-6.
Pavlovic D, Tamburic V, Stojanovic I, Kocic G, Jevtovic T, Dordevic V. Oxidative stress as marker of positive symptoms in schizophrenia. Medicine and Biology. 2002;9(2):157-61.
Rukmini MS, Benedicta D´Souza and Vivian D´Souza. Superoxide dismutase and catalase activities and their correlation with malondialdehyde in schizophrenic patients. Indian J Clin Biochem. 2004;19(2):114-8.
Dadheech G, Mishra S, Shiv Gautam, Sharma P. Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry. 2008;50:16-20.
Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y, Zhou DF. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res. 2006;81(2-3):291-300.
McCreadie RG, MacDonald E, Wiles D, Campbell G, Paterson JR. The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects. The British Journal of Psychiatry. 1995;167:610-7.
Ben Othmen L, Mechri A, Fendri C, Bost M, Chazot G, Gaha L, Kerkeni A. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):155-9.
Sarandol A, Kirli S, Akkaya C, Altin A,Demirci M, Sarandol E. Oxidative-antioxidative systems and their relation with serum S100B level in patients with schizophrenia: Effects of short term antipsychotic treatment. Progress in neuropsycho pharmacology and biological psychiatry. 2007;31:1164-9.
Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder Cell Biochem Funct. 2002;20(2):171-5.
Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry. 2001;6(1):66-73.
